Trastuzumab in early-stage breast cancer: the question of treatment timing

Pharmacoeconomics. 2008;26(10):807-9. doi: 10.2165/00019053-200826100-00001.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / economics
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / economics
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Female
  • Humans
  • Neoplasm Staging
  • Time Factors
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Trastuzumab